Disease | Mediators inhibited by AT1 blockade | Reference |
---|---|---|
Cardiovascular disease | NFκB, 'markers of oxidation inflammation and fibrinolysis' | 66 |
Cardiovascular disease | TGF-β | 67 |
Cardiovascular disease | TNF-α, IL-6, ICAM-1, VCAM-1 | 18 |
Cardiovascular disease | PAI-1 | 19 |
Cardiovascular disease | Surface adhesion molecules | 68,69 |
Cardiovascular disease | MCP in Hypercholesterolemia associated endothelial dysfunction | 70 |
Kidney disease | None noted in this study. | 71 |
Pancreatitis | (Key markers of the disease) | 72 |
Liver fibrosis and cirrhosis | 'TGF-β and pro-inflammatory cytokines' | 21 |
Skin disease | None noted in this study. | 73 |
Osteoporosis | 'Markers of inflammation' | 74 |
Alzheimer's, Huntington's and Parkinson's | (TGF-β [75], over expression of AT1 and AT2 noted in affected brain areas) | 75–78 |